Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286493384> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4286493384 abstract "Abstract Angiotensin-converting enzyme inhibitors (ACEI) such as benazepril are commonly prescribed in both humans and dogs with heart disease to mitigate the renin-angiotensin-aldosterone system (RAAS); however, the dose-dependent effects of benazepril on comprehensive RAAS components remain unknown. In this study, nine purpose-bred healthy dogs received three different dosages of oral benazepril (0.125 mg/kg, 0.25 mg/kg, or 0.5 mg/kg) in a randomized crossover design following induction of RAAS activation by consuming a low-sodium diet. Blood samples were collected at serial time intervals after benazepril dosing to measure plasma benazeprilat (active metabolite of benazepril) and serum RAAS biomarkers. Blood pressure and echocardiogram were performed at baseline and after each benazepril administration. Time-weighted averages for RAAS biomarkers for 12 hours post-dose and hemodynamic variables were compared between dosing groups using Wilcoxon rank-sum testing. Compared to the lowest dosage of benazepril (0.125 mg/kg), the highest dosage (0.5 mg/kg) resulted in lower time-weighted average values of angiotensin (Ang) II (-38%, P = 0.004), Ang1-5 (-53%, P = 0.001), ACE-S (surrogate for ACE activity; -59%, P = 0.0002), and ALT-S (surrogate for alternative RAAS activity; -22%, P = 0.004), and higher values of AngI (+ 78%, P = 0.014) and PRA-S (surrogate for plasma renin activity; +58%, P = 0.040). There were no relevant differences between dosing groups for blood pressure or echocardiographic variables. Knowledge of dose-dependent alterations in biomarkers of the classical and alternative RAAS pathways could help inform clinical trials for dosage optimization in both dogs and humans." @default.
- W4286493384 created "2022-07-22" @default.
- W4286493384 creator A5000396447 @default.
- W4286493384 creator A5007815909 @default.
- W4286493384 creator A5020391614 @default.
- W4286493384 creator A5029634501 @default.
- W4286493384 creator A5031092581 @default.
- W4286493384 creator A5054485647 @default.
- W4286493384 creator A5063827511 @default.
- W4286493384 creator A5081656232 @default.
- W4286493384 creator A5091001088 @default.
- W4286493384 date "2022-07-21" @default.
- W4286493384 modified "2023-10-18" @default.
- W4286493384 title "Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs" @default.
- W4286493384 doi "https://doi.org/10.21203/rs.3.rs-1858200/v1" @default.
- W4286493384 hasPublicationYear "2022" @default.
- W4286493384 type Work @default.
- W4286493384 citedByCount "0" @default.
- W4286493384 crossrefType "posted-content" @default.
- W4286493384 hasAuthorship W4286493384A5000396447 @default.
- W4286493384 hasAuthorship W4286493384A5007815909 @default.
- W4286493384 hasAuthorship W4286493384A5020391614 @default.
- W4286493384 hasAuthorship W4286493384A5029634501 @default.
- W4286493384 hasAuthorship W4286493384A5031092581 @default.
- W4286493384 hasAuthorship W4286493384A5054485647 @default.
- W4286493384 hasAuthorship W4286493384A5063827511 @default.
- W4286493384 hasAuthorship W4286493384A5081656232 @default.
- W4286493384 hasAuthorship W4286493384A5091001088 @default.
- W4286493384 hasBestOaLocation W42864933841 @default.
- W4286493384 hasConcept C126322002 @default.
- W4286493384 hasConcept C126894567 @default.
- W4286493384 hasConcept C134018914 @default.
- W4286493384 hasConcept C138976137 @default.
- W4286493384 hasConcept C162156334 @default.
- W4286493384 hasConcept C198710026 @default.
- W4286493384 hasConcept C27016395 @default.
- W4286493384 hasConcept C2777288759 @default.
- W4286493384 hasConcept C2777363265 @default.
- W4286493384 hasConcept C2778525890 @default.
- W4286493384 hasConcept C2779838083 @default.
- W4286493384 hasConcept C2908929049 @default.
- W4286493384 hasConcept C71924100 @default.
- W4286493384 hasConcept C84393581 @default.
- W4286493384 hasConcept C98274493 @default.
- W4286493384 hasConceptScore W4286493384C126322002 @default.
- W4286493384 hasConceptScore W4286493384C126894567 @default.
- W4286493384 hasConceptScore W4286493384C134018914 @default.
- W4286493384 hasConceptScore W4286493384C138976137 @default.
- W4286493384 hasConceptScore W4286493384C162156334 @default.
- W4286493384 hasConceptScore W4286493384C198710026 @default.
- W4286493384 hasConceptScore W4286493384C27016395 @default.
- W4286493384 hasConceptScore W4286493384C2777288759 @default.
- W4286493384 hasConceptScore W4286493384C2777363265 @default.
- W4286493384 hasConceptScore W4286493384C2778525890 @default.
- W4286493384 hasConceptScore W4286493384C2779838083 @default.
- W4286493384 hasConceptScore W4286493384C2908929049 @default.
- W4286493384 hasConceptScore W4286493384C71924100 @default.
- W4286493384 hasConceptScore W4286493384C84393581 @default.
- W4286493384 hasConceptScore W4286493384C98274493 @default.
- W4286493384 hasLocation W42864933841 @default.
- W4286493384 hasOpenAccess W4286493384 @default.
- W4286493384 hasPrimaryLocation W42864933841 @default.
- W4286493384 hasRelatedWork W1972017951 @default.
- W4286493384 hasRelatedWork W2134525082 @default.
- W4286493384 hasRelatedWork W2136465695 @default.
- W4286493384 hasRelatedWork W2148312174 @default.
- W4286493384 hasRelatedWork W2186146983 @default.
- W4286493384 hasRelatedWork W2324352442 @default.
- W4286493384 hasRelatedWork W2348310819 @default.
- W4286493384 hasRelatedWork W2360332229 @default.
- W4286493384 hasRelatedWork W2386445091 @default.
- W4286493384 hasRelatedWork W4255412210 @default.
- W4286493384 isParatext "false" @default.
- W4286493384 isRetracted "false" @default.
- W4286493384 workType "article" @default.